Archive
Home / Media Centre / Archive
Here you can find the archive of all Press Releases prior to 2023
Filter by date:
Showing 1262 press releases before 2023
-
Lynparza recommended for approval in the EU by CHMP for BRCA-mutated metastatic castration-resistant prostate cancer
-
Lynparza recommended for approval in EU by CHMP as 1st-line maintenance treatment with bevacizumab for HRD-positive advanced ovarian cancer
-
Lynparza reduced the risk of death by 31% in BRCA1/2 or ATM-mutated metastatic castration-resistant prostate cancer in PROfound Phase III trial
-
Tagrisso reduced the risk of disease recurrence in the brain by 82% in the adjuvant treatment of early-stage EGFR-mutated lung cancer
-
Lynparza improved median time patients lived without disease progression to over four and half years in BRCA-mutated advanced ovarian cancer vs. just over one year with placebo
-
Imfinzi demonstrated unprecedented survival in unresectable, Stage III non-small cell lung cancer with an estimated 50% of patients surviving four years
-
AstraZeneca acquires oral PCSK9 inhibitor programme from Dogma Therapeutics
-
COVID-19 vaccine AZD1222 clinical trials resumed in the UK
-
AstraZeneca to list US ADR equity and all US debt securities on Nasdaq
-
Fasenra met both co-primary endpoints of reduced nasal polyp size and blockage in the OSTRO Phase III trial for patients with chronic rhinosinusitis with nasal polyps
Latest articles and press releases
All of our latest press releases and articles are available to explore
Use a maximum of two downloads here
